Transfusion-transmitted infections

被引:125
作者
Bihl, Florian [1 ]
Castelli, Damiano
Marincola, Francesco
Dodd, Roger Y.
Brander, Christian
机构
[1] Harvard Univ, Sch Med, Partners AIDS Res Ctr, Massachusetts Gen Hosp, Boston, MA 02115 USA
[2] Swiss Red Cross Blood Transfus Serv So Switzerlan, Lugano, Switzerland
[3] NIH Clin Ctr, HLA Typing Lab, Bethesda, MD USA
[4] Amer Red Cross, Holland Lab, Rockville, MD USA
关键词
WEST-NILE-VIRUS; HEPATITIS-B-VIRUS; NUCLEIC-ACID TECHNOLOGY; PARVOVIRUS B19 TRANSMISSION; CREUTZFELDT-JAKOB-DISEASE; PLASTIC CULTURE BOTTLES; BLOOD-DONORS; PATHOGEN INACTIVATION; BACTERIAL-CONTAMINATION; UNITED-STATES;
D O I
10.1186/1479-5876-5-25
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Although the risk of transfusion-transmitted infections today is lower than ever, the supply of safe blood products remains subject to contamination with known and yet to be identified human pathogens. Only continuous improvement and implementation of donor selection, sensitive screening tests and effective inactivation procedures can ensure the elimination, or at least reduction, of the risk of acquiring transfusion transmitted infections. In addition, ongoing education and up-to-date information regarding infectious agents that are potentially transmitted via blood components is necessary to promote the reporting of adverse events, an important component of transfusion transmitted disease surveillance. Thus, the collaboration of all parties involved in transfusion medicine, including national haemovigilance systems, is crucial for protecting a secure blood product supply from known and emerging blood-borne pathogens.
引用
收藏
页数:11
相关论文
共 145 条
[1]   SEN virus: epidemiology and characteristics of a transfusion-transmitted virus [J].
Akiba, J ;
Umemura, T ;
Alter, HJ ;
Kojiro, M ;
Tabor, E .
TRANSFUSION, 2005, 45 (07) :1084-1088
[2]  
Alkassab Firas, 2006, Am J Med, V119, pe1, DOI 10.1016/j.amjmed.2005.11.008
[3]   Protecting the blood supply from emerging pathogens: The role of pathogen inactivation [J].
Allain, JP ;
Bianco, C ;
Blajchman, MA ;
Brecher, ME ;
Busch, M ;
Leiby, D ;
Lin, L ;
Stramer, S .
TRANSFUSION MEDICINE REVIEWS, 2005, 19 (02) :110-126
[4]  
*AM ASS BLOOD BANK, 2004, AABB B
[5]   Hemovigilance network in France:: organization and analysis of immediate transfusion incident reports from 1994 to 1998 [J].
Andreu, G ;
Morel, P ;
Forestier, F ;
Debeir, J ;
Rebibo, D ;
Janvier, G ;
Hervé, P .
TRANSFUSION, 2002, 42 (10) :1356-1364
[6]  
[Anonymous], 2003, BIODRUGS, V17, P66
[7]  
[Anonymous], CDR WEEKLY
[8]  
[Anonymous], 2002, Australian Prudential Standards on outsourcing for banks
[9]   Factor VIII von Willebrand factor complex in methylene blue-treated fresh plasma [J].
Aznar, JA ;
Molina, R ;
Montoro, JM .
TRANSFUSION, 1999, 39 (07) :748-750
[10]   Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients [J].
Benjamin, RJ ;
McCullough, J ;
Mintz, PD ;
Snyder, E ;
Spotnitz, WD ;
Rizzo, RJ ;
Wages, D ;
Lin, JS ;
Wood, L ;
Corash, L ;
Conlan, MG .
TRANSFUSION, 2005, 45 (11) :1739-1749